Updating results…
What is ALS Phase 3 Study TRO19622?
NCT01285583 is an open-label safety extension study of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) patients treated with riluzole. The drug TRO19622 is also known as olesoxime. Other study names are TRO19622 CL E Q 1425-1.
Reported Purpose & Perceived Effectiveness
| Perceived Effectiveness | |||||||
|---|---|---|---|---|---|---|---|
| Purpose | # of patients | # of patients with evaluations | Major | Moderate | Slight | None | Can’t tell |
| Participate in clinical trial | 3 | 2 |
|
||||
See all 3 patients currently using ALS Phase 3 Study TRO19622
Mouse over the table for more information
Reported Stop Reasons
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
| Did not seem to work | 1 |  |
|
| Other | 1 | |
See all 2 patients who’ve stopped using ALS Phase 3 Study TRO19622
Reported Duration See details about how long patients take this treatment ▼
Reported Adherence, Burden & Cost See details from patient evaluations ▼
Adherence
Taking treatment as prescribed
Adherence of ALS Phase 3 Study TRO19622
Always |
3 | 100% |
|
|---|---|---|---|
Usually |
0 | 0% |
|
Sometimes |
0 | 0% |
|
Never |
0 | 0% |
|
Burden
Difficulty being on treatment
Burden of ALS Phase 3 Study TRO19622
Very |
0 | 0% |
|
|---|---|---|---|
Somewhat |
0 | 0% |
|
A little |
1 | 33% |
|
Not at all |
2 | 67% |
|
Cost
Paid out of pocket
Cost of ALS Phase 3 Study TRO19622
$200+ |
0 | 0% |
|
|---|---|---|---|
$100-199 |
0 | 0% |
|
$50-99 |
0 | 0% |
|
$25-49 |
0 | 0% |
|
< $25 |
1 | 100% |
|
0 helpful marks
